• info@icbcongress.com
• English
• Persian

• Login

Create Free Account

INTERNATIONAL CONGRESS OF

CancerGenetics

• Investigation anticancer role of very low frequency electromagnetic field and doxorubicin treatment on cell line MDA-MB-231 to changes in the expression of genes CD44+/-CD24, CD133,CD326,ALDH

• Behnaz Habibinia,¹ Flora Forouzesh,² Mohammad Amin Javidi,^3,*
  1. Department of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
  2. Department of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
  3. Integrative Oncology Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran
  
  
  
• Introduction: Breast cancer, particularly TNBC, is aggressive with a poor prognosis due to its resistance to conventional therapies. The MDA-MB-231 cell line serves as a model for this aggressive subtype, where despite the efficacy of doxorubicin (DOX), the development of drug resistance remains a significant challenge. According to the clonal evolution theory, cancer originates from a single mutated cell, which accumulates genetic mutations over time, enabling certain clones to become resistant to therapies like DOX. Additionally, the cancer stem cell (CSC) hypothesis suggests that CSCs, a subpopulation within tumors, drive tumor progression, metastasis, and recurrence, contributing to resistance. Emerging research indicates that ELF-EMF could enhance chemotherapy effectiveness by targeting CSCs population. This study evaluates the combined effects of ELF-EMF and DOX on MDA-MB-231 cells, focusing on key CSC markers (CD44, CD133, CD326, ALDH) to reduce CSCs population and improve treatment outcomes.
• Methods: MDA-MB-231 cells were exposed to ELF-EMF (1 Hz, 100 mT) for 2 hours daily over 5 days. Four treatment groups were established: Sham, ELF, DOX, and ELF+DOX. Cell viability and apoptosis were assessed using MTT and Annexin V/PI assay and CD44+/-CD24. Gene expression changes in CD44, CD133, CD326, and ALDH were analyzed using real-time PCR.
• Results: Cell viability and apoptosis were assessed using MTT and Annexin V/PI assay and CD44+/-CD24. Gene expression changes in CD44, CD133, CD326, and ALDH were analyzed using real-time PCR. DOX Group: Moderate reduction in CD44+/-CD24 expression. ELF+DOX Group: Significant reduction, highlighting the combined effect in targeting CSCs. DOX Group: Moderate reduction in CD44+/-CD24 expression. ELF+DOX Group: Significant reduction, highlighting the combined effect in targeting CSCs.
• Conclusion: The combination of ELF-EMF and DOX showed potential in reducing the expression of CSC-related genes, particularly CD326, and increased apoptosis in MDA-MB-231 cells. These findings suggest that ELF-EMF could serve as an adjunct to conventional chemotherapy, improving treatment outcomes for TNBC by targeting CSCs population.
• Keywords: MDA-MB-231,Breast cancer, ELF-EMF, Doxorubicin, Cancer Stem cells